First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
about
Chlorambucil for the treatment of patients with chronic lymphocytic leukaemia, or small lymphocytic lymphomaThe role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapiesOfatumumab plus chlorambucil as a first-line therapy in less fit patients with chronic lymphocytic leukemia: analysis of COMPLEMENT1 and other monoclonal antibodies association dataProfile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemiaImmune reconstitution in chronic lymphocytic leukemiaSystematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trialsManagement of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.First-line treatments for chronic lymphocytic leukaemia: interpreting efficacy data by network meta-analysis.Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trialInteractions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials.A phase II study of two dose levels of ofatumumab induction followed by maintenance therapy in symptomatic, previously untreated chronic lymphocytic leukemia.Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsFirst-line treatment of chronic lymphocytic leukemia: role of alemtuzumab.Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemiaLenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.How I treat CLL up front.U.S. Food and drug administration approval: rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia.Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic modelAnti-CD37 antibodies for chronic lymphocytic leukemia.Chronic lymphocytic leukemia: planning for an aging populationChemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.Choosing first-line therapy for chronic lymphocytic leukemia.Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis.Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach.IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemiaMiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaTherapeutic advancement of chronic lymphocytic leukemia.Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US iRandomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaChronic lymphocytic leukemia: inception to cure: are we there?Treatment options for high-risk chronic lymphocytic leukaemia.Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG).
P2860
Q24236385-6C62123A-A5BA-4F84-99DD-968FF6B3D2BFQ24605471-16B5F541-B069-490C-9001-34812E6F777EQ26738934-C24BB823-C7E3-482D-B6E5-26A10D227FF1Q26781163-85BC0D18-D47C-42B6-B239-8D8568AF4B17Q26865561-A7397F2B-2D10-49E8-837E-0EB44D428448Q27001163-3664BFC4-EE6E-4EA2-9258-FF73BD565005Q30243914-12FF7056-DA58-4FAD-89EF-84DFE39E82ADQ30243968-BBC44224-3DFF-456C-B62E-6B517FA93373Q30801095-E7962D61-35EF-4A8A-BA29-3DA99C450A70Q30891802-CF7F5A2B-3710-449B-B7F9-251530A9A0B5Q33394947-8F56629E-ED54-44D5-AE01-A4358EA42D94Q33406478-CD350556-1526-4023-AC60-3D2E75AED4D8Q33412064-DD5F3484-854B-4740-BDEF-422A53471602Q33695990-12E800D8-E2FC-4E58-883B-0CA1961A893AQ33880538-244B440F-3856-408C-A32A-4876B44E25ECQ33913537-54EE563F-4642-48B0-93B1-5A00B65A28E2Q33956034-A76761D4-148F-4BF5-AF1D-7C3FE9381120Q34008584-5D854774-E39E-4F51-8700-8DF43AE57927Q34009041-7A93CCE0-DD93-4496-925F-F3AEE43FF26FQ34137158-0F587198-13E4-4393-87D6-EE0264B535ABQ34157931-5E110489-2300-40B4-B32E-FCF5E7CDF20AQ34272532-AED4D97D-A705-40E5-A0F9-4A381F4BE32CQ34405641-9C4BF65F-5F4B-431F-B3F1-07246756734FQ34560909-C617363D-CAA3-4F14-92B8-41698703F823Q34879367-3A7463F4-E8E5-4A6E-BE0F-3E2B2EDE7784Q35110582-54539DC5-842C-49F1-AC5A-F6FC6D97C9E9Q35123154-DB7D68C8-DBE4-455C-9256-067CF68EA06CQ35124844-EC1746FE-A07B-445D-9540-C9D971E3E9D5Q35714606-5DE12F6D-8894-4001-ABB8-3DAE0574F6B7Q35794457-48ADF635-EC3D-4591-9000-2B0EC89969EDQ35814897-E3965C33-7735-4B65-A6BE-C6CBCD0AB6B8Q35889836-642DABCC-1290-4AC3-9A08-D510C5CD6C1BQ35958056-69F43812-4D94-4458-A5A9-7AD8FF8497EBQ36300303-012317E7-BDB7-4DB0-8765-1014933E4166Q36397924-F93CC85A-7279-4B60-8CB1-5814766DF753Q36443141-EDB2594E-BF57-49F1-875E-EA2BEEFBAD51Q36490049-385BB1C4-5373-4A91-AB63-207CC9607E76Q36609259-65F162E7-606C-41D5-B1A8-47F6EDDD2180Q36612587-BB4716B4-830E-453D-B1F4-9C3E8F995F97Q36779681-84CAE729-AA49-486A-B8A2-A37CEA7EA189
P2860
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
First-line therapy with fludar ...... chronic lymphocytic leukemia.
@en
type
label
First-line therapy with fludar ...... chronic lymphocytic leukemia.
@en
prefLabel
First-line therapy with fludar ...... chronic lymphocytic leukemia.
@en
P2093
P50
P1433
P1476
First-line therapy with fludar ...... chronic lymphocytic leukemia.
@en
P2093
Anna-Maria Fink
Anne Westermann
Barbara F Eichhorst
Bertold Emmerich
Carmen D Schweighofer
Clemens M Wendtner
German CLL Study Group (GCLLSG)
Günter Brittinger
Kirsten Fischer
Manuela A Bergmann
P304
P356
10.1182/BLOOD-2009-02-206185
P407
P577
2009-07-15T00:00:00Z